Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2017 Jan-Mar;24(1):30-42.
doi: 10.4103/meajo.MEAJO_276_16.

Update on the Epidemiology and Antibiotic Resistance of Ocular Infections

Affiliations

Update on the Epidemiology and Antibiotic Resistance of Ocular Infections

Darlene Miller. Middle East Afr J Ophthalmol. 2017 Jan-Mar.

Abstract

Purpose: The purpose of this review is to provide an update on the epidemiology and current antibiotic-resistant threats in ophthalmology.

Methods: Trends in frequency and antibiotic-nonsusceptible profiles during an 11 year-period (2005-2015) were evaluated and compared with the 5-year Antibiotic Resistance Monitoring in Ocular Microorganism (ARMOR) study.

Results: Trends in the current review confirmed the continued high rates of fluoroquinolone nonsusceptbility circulating among ocular methicillin-susceptible Staphylococcus aureus, methicillin-susceptible Staphylococcus epidermidis, methicillin-resistant S. aureus, and methicillin-resistant S. epidermidis isolates as well as the detection of uncommon, but emerging resistance (<5%) for Streptococcus pneumoniae, Streptococcus viridans group, Haemophilus influenzae, and Pseudomonas aeruginosa. We documented significant differences in empirical fluoroquinolone and aminoglycoside coverage for the top three ocular pathogens (coagulase-negative staphylococci, S. aureus, and P. aeruginosa) in general and for corneal isolates between the Miami and the ARMOR studies. Collectively, the coverage for Miami was 74% versus 65.9% for ARMOR (P < 0.0001, 5.3674-10.8042) for ciprofloxacin and 95.9% versus 84.2% for aminoglycosides (gentamicin/tobramycin) (P < 0.0001, 9.9925-13.3974). Monotherapy coverage for ciprofloxacin and levofloxacin for the most recent 5 years (2011-2015) was 76.6% and 77.1%, respectively. Combination therapy with a fluoroquinolone and vancomycin and/or vancomycin and an aminoglycoside provided coverage for 99% and 98% of the isolates, respectively.

Conclusion: The etiology of ocular pathogens is patient, source, and geography specific. The true incidence and/or prevalence are unknown. Fluoroquinolone monotherapy as standard therapy for common ocular infections needs to be reassessed. Ophthalmologists must become proactive and join the crusade to develop practical and prudent strategies for the administration of topical antibiotics.

Keywords: Antibiogram; antibiotic resistance; diversity; nonsusceptibility.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
Recovery trends by organism groups

Similar articles

Cited by

References

    1. McDonald M, Blondeau JM. Emerging antibiotic resistance in ocular infections and the role of fluoroquinolones. J Cataract Refract Surg. 2010;36:1588–98. - PubMed
    1. Bertino JS., Jr Impact of antibiotic resistance in the management of ocular infections: The role of current and future antibiotics. Clin Ophthalmol. 2009;3:507–21. - PMC - PubMed
    1. Antibiotic resistance threats in the United States, 2013. Atlanta: CDC; 2013. [Last accessed on 2016 Jul 14]. Centers for Disease Control and Prevention (CDC) Available from: http://www.cdc.gov/drugresistance/threat-report-2013/pdf/arthreats-2013-... .
    1. Kowalski RP. Is antibiotic resistance a problem in the treatment of ophthalmic infections? Expert Rev Ophthalmol. 2013;8:119–26.
    1. Iwalokun BA, Oluwadun A, Akinsinde KA, Niemogha MT, Nwaokorie FO. Bacteriologic and plasmid analysis of etiologic agents of conjunctivitis in Lagos, Nigeria. J Ophthalmic Inflamm Infect. 2011;1:95–103. - PMC - PubMed

Substances